司美格鲁肽与恩格列净单用及联用对2型糖尿病患者肾脏氧合与灌注的影响:一项随机试验
在丹麦奥胡斯大学医院开展的随机试验纳入120例2型糖尿病且心血管病高危患者,分四组接受司美格鲁肽1.0 mg、恩格列净10 mg、两药联用或安慰剂治疗32周。预设80人行MRI评估肾脏氧合,结果显示恩格列净降低肾髓质氧合,司美格鲁肽降低肾脏灌注但不影响氧合,研究假设被拒绝。
要点
- 恩格列净组32周时肾髓质R2*为25.4 Hz,安慰剂组为24.5 Hz,R2*升高对应氧合降低(p=0.016)。
- 司美格鲁肽降低肾皮质和髓质灌注,但未影响肾脏氧合。
- 恩格列净升高促红细胞生成素和血细胞比容,三种活性治疗均降低GFR但未降低UACR。
核心结论
- 研究假设(司美格鲁肽、恩格列净或联用改善肾脏氧合)被拒绝;恩格列净反而降低肾髓质氧合,司美格鲁肽显著降低肾脏灌注但不影响氧合。
研究设计与样本
- 在丹麦奥胡斯大学医院开展的随机试验,120例2型糖尿病(HbA1c ≥48 mmol/mol [6.5%])且心血管病高危(年龄≥50岁)患者随机分四组(每组n=30)治疗32周。
- 四组分别为司美格鲁肽1.0 mg开放标签、恩格列净10 mg盲法、两药联用(司美格鲁肽开放标签加恩格列净盲法)和安慰剂片盲法。
- 预设80人(每组20人)行MRI评估肾脏氧合,采用计算机生成随机码密封信封分配干预。
主要发现
- 模型估计四组肾皮质和髓质基线R2*值相同,基线髓质R2*为24.5(95% CI 23.9, 24.9)Hz。
- 32周后髓质R2*在恩格列净组为25.4(95% CI 24.7, 26.2)Hz,安慰剂组为24.5(95% CI 23.9, 25.1)Hz(p=0.016),R2*越高对应氧合越低。
- 司美格鲁肽降低肾皮质和髓质灌注;恩格列净升高促红细胞生成素和血细胞比容。
- 三种活性治疗均降低GFR但未降低UACR。
- 报告10例严重不良事件,其中2例为司美格鲁肽相关便秘。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Glucagon-like peptide-1 receptor agonists (GLP-1ras) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) have shown kidney-protective effects. Improved kidney oxygenation and haemodynamic changes are suggested mechanisms; however, human data are scarce. We therefore investigated whether semaglutide (GLP-1ra), empagliflozin (SGLT2i) or their combination improve kidney oxygenation and perfusion. METHODS: The trial was undertaken at Aarhus University Hospital, Denmark. A total of 120 people with type 2 diabetes (HbA1c ≥48 mmol/mol [6.5%]) and at high risk of CVD (age ≥50 years) were randomised into four parallel groups (n=30 in each group) for 32 weeks: 1.0 mg semaglutide (open label); 10 mg empagliflozin (blinded to participants, caregivers, examiners and outcome assessors); their combination (1.0 mg semaglutide open label plus 10 mg empagliflozin blinded to participants, caregivers, examiners and outcome assessors); and placebo tablet (blinded to participants, caregivers, examiners and outcome assessors). Sequentially numbered, sealed envelopes containing computer-generated randomisation codes, provided by Glostrup Pharmacy, Glostrup, Denmark, determined the intervention. The two co-primary outcomes were change in kidney oxygenation and change in arterial stiffness. This paper reports on kidney oxygenation, for which 80 individuals as prespecified, 20 in each group, underwent MRI. We primarily hypothesised that kidney oxygenation would be improved in the active treatment groups compared with placebo after 32 weeks. Secondary outcomes included changes in kidney perfusion, erythropoietin, haematocrit, urine albumin/creatinine ratio (UACR) and GFR (measured using technetium-99m) compared with baseline and between treatment groups at week 32. RESULTS: Our model estimated a common baseline R2* value across all four groups in the cortex and the medulla. At baseline, the value was 24.5 (95% CI 23.9, 24.9) Hz in the medulla. After 32 weeks, the R2* values in the medulla were estimated to be 25.4 (95% CI 24.7, 26.2) Hz in the empagliflozin group and 24.5 (95% CI 23.9, 25.1) Hz in the placebo group (p=0.016) (higher R2* corresponds to a lower oxygenation). Semaglutide decreased perfusion in both the cortex and the medulla. Empagliflozin increased erythropoietin and haematocrit. All three active treatments decreased GFR but not UACR. Ten serious adverse events were reported, among them two occurrences of semaglutide-associated obstipation. CONCLUSIONS/INTERPRETATION: Our hypothesis, that semaglutide, empagliflozin or their combination improve kidney oxygenation, was rejected. On the contrary, empagliflozin induced a reduction in medullary kidney oxygenation. Semaglutide substantially reduced kidney perfusion without affecting oxygenation. TRIAL REGISTRATION: Clinicaltrialsregister.eu EudraCT 2019-000781-38 FUNDING: Novo Nordisk Foundation, Central Denmark Region Research Fund and Danish Medical Associations Research Foundation.
引用
- Gullaksen S, Vernstrøm L, Sørensen SS, et al. Separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and perfusion in people with type 2 diabetes: a randomised trial. Diabetologia. 2023. PMID: 36746803. doi:10.1007/s00125-023-05876-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。